Browse Articles
Discover research articles across all indexed journals
Low versus low-intermediate risk metastatic renal cell carcinoma (mRCC): Contemporary data from the International mRCC Database Consortium (IMDC).
505 Background: The IMDC model has been effectively used to predict patients’ (pts) outcomes with mRCC, significantly guiding treatment decisions in the era of immune checkpoint inhibitors (ICIs) that have improved survival. In this study, we aim to characterize the clinical outcomes between patients classified as low (L, IMDC score of 0) vs. low-intermediate (L/I, IMDC score of 1) categories. Methods: Data of pts with mRCC receiving first-line (1L) ICI-based therapies with IMDC scores 0 or 1 was collected from the IMDC. Pts with score 1 were further subdivided into 4 groups based on their individual risk factor: low hemoglobin (Hb), Karnofsky Performance Status (KPS) <80, time from diagnosis (dx) to treatment < 1 year, and other risk factors including elevated neutrophils, platelets, and calcium. Overall survival (OS) and time to treatment failure (TTF) were analyzed using Cox regression models. Logistic regression was used to compare an objective response rate (ORR) according to RECIST 1.1. Results: Among the 803 eligible patients, 283 were classified as L and 520 as L/I. Patients' median age was 60 years (Q1-Q3: 23-88 years). The distribution of patients across specific risk categories within the IMDC score 1 group is detailed in the table. Compared to those with an IMDC score of 0, patients with a score of 1 related specifically to low performance status was associated with a shorter TTF (HR: 2.93, p<0.0001) and ORR (OR: 0.24, p=0.002). Anemia was significantly associated with decreased OS (HR: 1.61, p=0.002), shorter TTF (HR: 1.63, p=0.0002), and reduced ORR (OR: 0.65, p=0.05). Time from diagnosis to initiation of treatment within 1 year was significantly associated with shorter TTF (HR: 1.39, p=0.0015). Conclusions: Anemia and low-performance status emerged as the most informative factors differentiating prognosis between L and L/I IMDC risk groups receiving 1L ICI-based treatment. Molecular studies could further clarify these differences, aiding risk stratification and personalized treatment. Clinical outcomes of patients with mRCC based on risk factors. IMDC =0(N=283) IMDC=1 Low Hb(N=133) Time from dx to treatment <1 year (N=331) KPS <80 (N=21) Other risk factors (N=35) HR for OS* (95% CI) Ref. 1.61 (1.08-2.42)p-value = 0.002 1.11 (0.8-1.56)p-value = 0.55 1.9(0.819-4.408)p-value = 0.135 1.16 (0.55-2.42)p-value = 0.7 HR for TTF* (95% CI) Ref. 1.63 (1.26-2.10)p-value = 0.0002 1.39(1.13-1.7)p-value = 0.0015 2.88 (1.73-4.774)p-value <0.0001 1.9 (0.73-1.91)p-value = 0.47 OR for ORR** (95% CI) Ref. 0.65 (0.42-0.99)p-value = 0.05 1.1 (0.8-1.52)p-value = 0.52 0.22 (0.05-0.66)p-value = 0.02 0.99 (0.48 – 2)p-value = 0.98 *Analysis included 781 patients for OS and 778 for TTF after excluding cases with missing data. **78 not evaluable patients were included as non-responders.
Real-world outcomes of first-line dual immunotherapy versus combination VEGF immunotherapy in intermediate-poor risk metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Data Consortium (IMDC).
477 Background: Multiple phase 3 trials have established either dual immunotherapy with ipilimumab and nivolumab (IPI-NIVO) or immunotherapy with a VEGFR inhibitor (IO-VE) as standard-of-care first-line therapy for metastatic clear cell renal cell carcinoma (mRCC). We focused this analysis on patients with IMDC intermediate or poor risk where either IPI-NIVO or IO-VE would be standard. Methods: Using the IMDC database, we performed a retrospective analysis of patients with intermediate or poor risk disease (1 or more IMDC risk factors) who received first-line therapy with IPI-NIVO or an approved IO-VE combination (avelumab-axitinib, nivolumab-cabozantinib, pembrolizumab-axitinib, or pembrolizumab-lenvatinib). Baseline characteristics, objective response rates (ORR), time to next therapy (TTNT), and overall survival (OS) were compared between IPI-NIVO and IO-VE regimens by Cox regression analyses. Results: A total of 1,523 patients were identified of whom 72.9% received IPI-NIVO and 28.2% received IO-VE. Baseline characteristics of our cohort are summarized in the table. Median follow-up was 24 months. The ORR was lower with IPI-NIVO compared with IO-VE (39.1% vs 48.0%; p = 0.004). Median TTNT was shorter in IPI-NIVO than IO-VE (10.4 months, 95% CI 9.4-11.7 vs 18.6 months, 95% CI 16.3-24.6; p <0.0001). Median OS was similar between groups at 35.4 months (95% CI: 31.4-41.9) and 35.6 months (95% CI: 28.9-44.1) for IPI-NIVO and IO-VE respectively (p = 0.277), and there were no significant differences when intermediate and poor risk groups were analyzed separately. Median OS in IO-VE vs IPI-NIVO was not significantly different when adjusted by IMDC criteria, brain, bone and liver metastases (HR 0.87, 95% CI 0.71-1.06; p=0.165). Conclusions: In a real-world setting amongst patients with IMDC intermediate-poor risk disease, IPI-NIVO and IO-VE strategies show similar survival outcomes although longer follow-up will be necessary to assess the tails of these survival curves. IO-VE is associated with a greater response rate compared with IPI-NIVO. Baseline characteristics. IPI-NIVON = 1110 IO-VEN = 413 p-value Male 808 (72.8) 303 (73.4) 0.823 IMDC Intermediate/Poor Risk 730/280 (65.8/34.2) 274/139 (66.3/33.7) 0.832 Pre-existing autoimmune condition 16 (2.6) 12 (4.6) 0.133 Non-clear cell histology 139 (15.9) 57 (16.4) 0.844 Sarcomatoid 147 (21.3) 50 (17.2) 0.1437 Nephrectomy 613 (55.3) 239 (57.9) 0.374 Brain metastasis 90 (8.4) 23 (5.7) 0.084 Bone metastasis 373 (34.3) 173 (42.5) 0.003 Liver metastasis 218 (20.2) 65 (16.0) 0.063
Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors.
791 Background: Radical nephroureterectomy (RNU) is the standard treatment for localized high-risk upper tract urothelial carcinoma (UTUC). However, the predominance of UTUC in elderly populations with significant comorbidities necessitates alternative treatment strategies that prioritize functional nephron preservation. This pilot study aims to assess the efficacy and safety of a comprehensive modality of kidney-sparing approach, comprising endoscopic Thulium laser ablation and perioperative systemic therapy (Disitamab vedotin [DV] and immune checkpoint inhibitors [ICIs]), in a carefully selected cohort of localized high-risk UTUC. Methods: This ongoing study, initiated in November 2021 at West China Hospital of Sichuan University, included selected patients with localized UTUC patients (cT≤2N0M0) characterized by conditions such as solitary kidney, bilateral tumors, impending/already renal insufficiency and individual refusal/ineligibility for RNU. The treatment protocol consisted of endoscopic biopsy and initial laser ablation, followed by 3-4 cycles of DV and ICIs administered every three weeks as induction therapy. Subsequently, patients underwent maximal endoscopic laser ablation. Those exhibiting efficient response received a 6-month course of DV and a 12-month course of ICIs as maintenance therapy. Co-primary endpoints were 1-yr disease-free survival (DFS) and conversion-free survival (CFS). Secondary endpoints included clinical complete response (cCR) rate, renal function benefits, and treatment safety. Results: Thirty-two patients were enrolled, with a median follow-up of 15 months. The majority of patients (26/32, 81.25%) were diagnosed with HER2-positive in biopsy-related IHC, including 3 cases of HER2 3+ and 23 cases of HER2 2+. During the follow-up, 17 local recurrences were observed in 10 patients and the 1-yr DFS rate was 68.75%. HER2 status was a significant predictive factor for local recurrence (OR, 0.15; 95% CI, 0.03, 0.91). Salvage RNU was performed in 2 patients, yielding a 1-yr CFS rate was 93.75%. The cCR rate is 78.13% (25/32). Postoperative renal function impairment was noted in 6 patients (18.75%). Mean eGFR improvements (ml/min/1.73m2) were observed with 3.15 at 1 month, 5.07 at 3 months, 2.41 at 6 months, and 3.97 at 12 months. Notably, no grade 3 or higher systemic toxicities were observed. Conclusions: Preliminary findings indicate that the combination of endoscopic Thulium laser ablation with perioperative systemic therapy (DV and ICIs) demonstrated promising efficacy and manageable safety in selected patients with localized high-risk UTUC. These results provide a solid foundation for the ongoing phase 2 trial (WUTSUP-03) and suggest a potential paradigm shift in the management of this challenging patient population.
The electric field influence on EC-0.18 eV electron trap level in (100)-oriented β-Ga2O3 crystals grown by the Czochralski method
In this Letter, we demonstrate the application of Deep Level Transient Spectroscopy (DLTS) and Laplace DLTS (L-DLTS) techniques to unintentionally doped β-Ga2O3 crystals grown by the Czochralski method. It is clearly shown that the capacitance signal associated with the electron emission from a trap level previously identified in the literature as E14 and characterized by an activation energy of 0.18 eV is found to be a superposition of electron emissions from two closely spaced energy levels. Furthermore, we noted that the corresponding L-DLTS signal splits into two well separated components with activation energies of 196 and 209 meV, and the splitting occurs as the electric field in the space charge region of a Schottky diode exceeds 2 × 107 V/m (0.2 MV/cm). Additionally, a strong dependency of DLTS and L-DLTS signals on the electric field strength and resulting enhancement of the electron emission from these two trap states agree well with the 1D Poole–Frenkel (PF) model, suggesting donor-like behavior of both states. Finally, we found that the barrier height for thermal emission of the electrons is significantly reduced in our samples by 121 meV due to the PF effect for experimental conditions corresponding to an electric field of 3.5 × 107 V/m (0.35 MV/cm).
Implementation and first report of the Brazilian Kidney Biopsy Registry
Background Kidney biopsy registries are valuable tools for guiding clinical practice and developing health policies. In 2021, the Brazilian Society of Nephrology (SBN) created the Brazilian Kidney Biopsy Registry (BKBR). This is the first BKBR report, presenting patient data from 2021. Methods BKBR is a web-based platform hosted on the BSN website, which contains patient demographics, clinical data, frequency, and distribution of histologic diagnosis of Brazilian adult native kidney biopsies. Results Of the 1012 cases registered in 2021, 954 cases were evaluated after excluding pediatric and kidney transplant cases. Twenty-one centers enrolled patients, with representation from all Brazilian regions. There was a slight predominance of females (52.6%), a mean age of 44.7 ± 16 years, and 13.6% of patients were >65 years old. The main indication for kidney biopsy was renal dysfunction (56%) and nephrotic syndrome (41.4%), respectively. At the time of the biopsy, 47.9% of the patients were hypertensive and 15.2% were diabetic. Although 66.2% of patients had eGFR ≤60ml/min/1.73m2 upon biopsy, the majority (60.2%) had mild interstitial fibrosis and tubular atrophy. The most frequent diagnosis in the BKBR was glomerular disease (74.8%). Lupus nephritis was the most frequent diagnosis of glomerular disease (22.6%), followed by IgA nephropathy (13%) and focal segmental glomerulosclerosis (12.2%). Conclusion This is the first report of a Nationwide registry of kidney biopsies in Brazil. This data provides pivotal information about the kidney disease profile in this country with continental dimensions.
Global sensitivity analysis of roof hazard factors based on information entropy and the surrogate model
Abstract The prevention and management of coal mine roof accidents remain challenging issues because it is difficult to evaluate and quantify the interaction effects of the disaster hazard factors objectively. This paper proposes a novel approach: combining information entropy and the surrogate model—and applies Sobol’s method, aiming to solve it and to obtain the hazard factors’ 1th and the global sensitivity value without human intervention. The results show that: (1) The complex logical relationships and interactions of roof hazard factors can be transformed into quantifiable numerical values by building a co-occurrence matrix of disaster factors and calculating its information entropy. (2) The sensitivity levels of roof hazard factors can be successfully distinguished and categorized into priority management and prevention or general management and prevention using the surrogate model and Sobol’s sensitivity method. The novel sensitivity analysis approach suggested in this study considers both the individual impacts of hazard factors and their interactions, offering a more thorough framework for risk assessment as well as a fresh perspective and tool for coal mine safety research.
Clinical outcomes disparities in prostate cancer in the Caribbean: Results from 504 patients from the Martinique cohort.
314 Background: Ethnic and geographic disparities in cancer care access is an issue. French West Indies has one of the world highest incidence of prostate cancer (PC) related to African ancestry in indigenous population and specific environmental carcinogens. The HOXB13 X285K germline mutation is linked to strong family risk and poor prognosis in men with PC. The HOXB13 study enrolled prospectively patients diagnosed with PC in order to determine the prevalence of HOXB13 X285K germline mutation in Martinique. We reported here clinical data from all the cohort. Methods: Patients with a history of PC were proposed to participate to this single center study. Germline HOXB13 X285K mutation screening was performed by sequencing germline DNA according to the Sanger method. We reported clinical-pathological features and outcomes from medical reports from patients enrolled. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Results: We reported a cohort from 504 patients diagnosed with PC between 1999 and 2024 in the unique institution of cancer care in Martinique. The prevalence of HOXB13 X285K germline mutation was 0.99% (5/504) in our cohort, higher than the rate of 0.01% in all comers previously reported. Median age was 63.5 years (36-91). A PC family history of 1st or 2nd degree was found in 33% (166/504). Median BMI was 25 kg/m² and was ≥30 kg/m² in 7.5 %. Risk assessment according to D’Amico was low, intermediate, and high in 11.7%, 35.3%, and 52% respectively. Out of 504 patients, 61 had d e novo metastatic PC (12.1%). The Gleason score was 6, 7, 8-10 in respectively 25%, 49.2%, and 24.2%. Concerning treatment of localized cancer, 44.2% received surgery (R1 in 34%), 47% radiotherapy, 39% hormonotherapy, 8.8% active surveillance, 5.2% brachytherapy and 0.2% HIFU. After local treatment, 34.5% relapsed with median PFS of 3.5 years. Median time between pathology results and therapy initiation was about 5 months (0-4030 days).With median follow up of 5.3 years (2 months-26 years), 42 patients were dead at the time of analyses, median OS was not reached. Conclusions: We reported data from a large homogenous cohort of PC from diversity. Indigenous population from Caribbean Island is underrepresented in clinical trials. However, this population seems to be diagnosed at a younger age, have a longer time from diagnosis to initiation of treatment, a lower access to clinical trials, and an adverse outcome than those diagnosed in the rest of mainland France addressing the disparities in cancer care access. The higher incidence of HOXB13 X285K germline mutations in this population may explain the aggressive profile. To note, this germline mutation was found 100 times higher in local population with PC than in general population (around 0.01%).
Evaluating the contribution of circulating tumor DNA (ctDNA) towards magnetic resonance imaging (MRI) in clinical staging and response assessment of patients with muscle-invasive bladder cancer (MIBC).
798 Background: In patients (pts) with MIBC, optimizing clinical staging (cT-stage) and response assessment after neoadjuvant therapies has become critical in order to envision next-generation bladder-sparing strategies. We have previously reported on the performance of bladder MRI to stage and predict the pathological response to pembrolizumab with the use of modified vesical-imaging reporting and data system (VI-RADS, PMID: 37803523). Using ctDNA yields the potential to increase the prediction of pathological stage, and improve the accuracy of the clinical complete response (cCR) definition. Methods: We report interim results from a prospective biomarker study assembling data from a platform of neoadjuvant trials testing novel perioperative therapies and radical cystectomy (RC) in pts with MIBC (NCT06341478). Pts were staged before and after neoadjuvant therapy with pelvic MRI; modified VI-RADS score consisted of the addition of VI-RADS 0 category to indicate no evidence of residual tumor. MRI images were assessed by 2 independent radiologists. ctDNA monitoring was assessed before and after neoadjuvant therapy and centralized using Signatera ctDNA Assay (Natera Inc., San Carlos, CA). Mean tumor molecules (MTM)/mL were reported. Fisher’s exact test was used for comparing groups. Results: From 07/23 to 09/24, 29 pts with available information on both MRI and ctDNA at baseline and/or after treatment, before RC, were collected. Nineteen (65.5%) had a cT2-stage, 4 received neoadjuvant nivolumab+abraxane (NCT04876313), 15 sacituzumab govitecan (SG) alone (NCT05226117) and 10 SG+pembrolizumab (NCT05535218). At baseline, 0/10 pts with VI-RADS 0-3 had detectable ctDNA vs 9/13 (69%) of VI-RADS 4-5 pts (p = 0.001). Mean baseline ctDNA count was 2.31 MTM/mL. Only 17.6% of cT2 pts revealed detectable ctDNA (mean: 2.51 MTM/mL) vs 100% cT3-4 (mean: 2.39 MTM/mL) (p < 0.001). Likewise, post-neoadjuvant therapy, 0/10 pts with VI-RADS 0-3 had detectable ctDNA vs 4/7 (57%) of VI-RADS 4-5 pts with a mean count of 294.8 MTM/mL (p = 0.010). 2/3 pts with clearance of ctDNA post-therapy had VI-RADS 4-5 scores post-therapy. After neoadjuvant treatment 11/14 (78.6%) pts with VI-RADS 0-3 achieved a pathologic complete response (pCR) vs 1/9 (11.1%) with VI-RADS 4-5 (p < 0.001). However, the only patient with pCR and post-neoadjuvant VI-RADS 3-4 relapsed. Post-neoadjuvant ctDNA was negative in 8/11 (72.7%) pts with pCR and in 0/5 without pCR (p = 0.023). Conclusions: Initial findings from a prospective biomarker study revealed a suboptimal association between local and systemic tumor assessment in pts with MIBC. In the effort of optimizing the definition of cCR to systemic therapy, ctDNA revealed critical limitations that would limit its use in bladder-sparing strategies. More mature data will be presented at the meeting. Clinical trial information: NCT06341478 .
Extensive necrosis as a prognostic indicator in metastatic RCC patients undergoing deferred cytoreductive nephrectomy after immunologic checkpoint inhibitor treatment.
468 Background: The role of cytoreductive nephrectomy (CN) in patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor (ICI)-based therapies remains under debate. Retrospective cohorts have reported shrinkage in the primary tumors and no residual tumor in primary specimens (pT0), however, the clinical relevance has not been explored. Assessing the pathological outcomes of CN following ICI may provide valuable information. Methods: This is a single-center retrospective analysis of metastatic/locally advanced RCC who underwent CN between May 2017 and September 2024 after ICI-based treatment. Demographic and clinicopathological were collected. The primary endpoint was the rate of patients with extensive necrosis (EN), defined as ≥ 95% of necrosis in the resected primary tumor. Progression-free survival (PFS) was calculated at two timepoints: from the date of ICI initiation (PFS1) and from the date of surgery (PFS2) until event (progression or death) or last follow-up, using the Kaplan-Meier method. Differences between groups (pts with EN in resected kidney vs not) were assed with the log-rank test and hazard ratios were calculated with Cox regression model. Correlations were made with the Fisher test between presence of EN and other categorical variables. Results: Twenty-five pts were identified, with a median age of 62 years (range, 40–83), and median follow-up of 31.5 months after initiating ICI. 84% were metastatic, with 84% receiving first-line ICI-based combinations (5 Ipi/Nivo;16 ICI-TKI), while the remaining 16% had second-line nivolumab. The median ICI exposure before surgery was 10.5 m (range, 2.1–42.7) in the entire cohort, 12.7 m (range, 2.1–28.8) in the EN subgroup and 10.3 m (range, 3.1–42.7) in the non-EN. Best overall radiological response prior to surgery included 4% CR, 68% PR and 28% SD. Pathological assessment revealed 76% clear cell, 16% unclassified and 8% papillary RCC and 16% had a sarcomatoid component. 40% of pts had ≥ 95 % necrosis, with half of these pts (20%) achieving pT0. The median PFS1 was numerically longer in pts with EN, not reached (NR) vs 27.7 m, (HR 0.33; 95% CI, 0.09 -1.26; p = 0.09). The median follow-up after surgery was 10 months, and the median PFS2 was longer in the EN subgroup, NR vs 9.7 m, (HR 0.2; 95% CI, 0.04–0.96; p < 0.05). No significant correlations were found between EN and Fuhrman grade, presence of sarcomatoid differentiation, treatment duration, or radiological response. Conclusions: ICI-based regimens showed activity in primary RCC tumors, leading to EN (≥ 95% of necrosis) in a subset of pts. Those who achieved EN appear to have reduced risk of disease progression.
Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.
544 Background: Non-clear cell renal cell carcinoma (nccRCC) accounts for approximately 25% of all renal cell carcinoma (RCC) and lacks standards of care. More recent data suggests the efficacy of anti-PD-(L)1 plus anti-CTLA-4 and immune checkpoint inhibitors combined with tyrosine-kinase inhibitors in the RCC. Cadonilimab (AK104) is a first-in-class tetravalent bispecific antibody that targets both PD-1 and CTLA-4, showing a manageable safety profile and favorable clinical benefits. Here we explore the efficacy and safety of cadonilimab in combination with axitinib in patients with advanced or metastatic nccRCC. Methods: Eligible patients had histologically confirmed advanced or metastatic nccRCC who had not previously received systemic therapy. Patients received cadonilimab (10 or 15 mg/kg q3w in phase Ib, and 10mg/kg q3w in phase II) in combination with axitinib (5mg bid) as first-line treatment until disease progression or intolerant to treatment. The primary endpoints were safety and objective response rate (ORR; RECIST v1.1). This study is registered with ClinicalTrials.gov, NCT05808608. Results: As of October 1, 2024, 26 patients were enrolled, median follow-up was 5.1 months (0.6-10.7 months). Twenty patients were available for efficacy assessment. Confirmed ORR was 55% (11/20), and disease control rate (DCR) was 95% (19/20). The median progression-free survival (PFS) was not reached. All patients experienced treatment-related adverse events (TRAEs), grade≥3 TRAEs occurred in 12 (46.2%) patients. Conclusions: Cadonilimab combined with axitinib demonstrated promising antitumoral efficacy and manageable toxicities in patients with advanced or metastatic nccRCC. The trial is an ongoing study, and complete results are awaited after completion of the enrollment and longer follow-up. Clinical trial information: NCT05808608 .
Ferroelectric tunnel junction based on Zr0.75Hf0.25O2/Al2O3 composite barrier
Ferroelectric tunnel junction (FTJ) with tunable tunnel electroresistance is promising for emerging nonvolatile memory applications. In this work, 6 nm-thick Hf-doped ZrO2 ferroelectrics with Zr : Hf = 3 : 1 (ZHO), exhibiting a high remanent polarization of 30 μC/cm2, was prepared and further used to build Pt/ZHO/Al2O3/W FTJ devices with adding 1 nm-thick Al2O3 dielectric layer to reduce the leakage. The FTJ delivered superior performance with a tunneling electroresistance ratio of over 7000, outperforming previously reported other FTJ devices based on hafnia/zirconia ferroelectrics. Under 100 ns single-pulse writing, the FTJ exhibited multiple stable states, good retention over 104 s, and switching endurance exceeding 5 × 104 cycles. Additionally, it delivered a relatively high read current density of 8 A/cm2 at 0.2 V. The results demonstrate that the ZHO/Al2O3 composite structure can effectively alter the tunneling barrier height and increase tunneling current, resulting in a large ON/OFF ratio. The results underscore a great potential of ZHO ferroelectrics in the future development of high-performance nonvolatile memory technologies.
Olympic combat sports and mental health in children and adolescents with disability: A protocol paper for systematic review
Introduction Mental health is important for children and adolescents, particularly those with disabilities. While the mental health advantages of sports participation are well-documented, the specific type of sport may have heightened relevance for children and adolescents with disabilities. The objective of this systematic review protocol is to outline the rationale and methodology for investigating how participation in Olympic combat sports influences the mental health outcomes of this unique population, which is more susceptible to developing mental health issues than their neurotypical counterparts. Methods and analysis A comprehensive search will be conducted across academic databases, including the Cochrane Library, ERIC, PsycINFO, PubMed, Scopus, SPORTDiscus, and Web of Science. The focus will be on identifying randomized and non-randomized controlled trials (RCTs and non-RCTs, respectively), and observational studies with control groups that explore the impact of Olympic combat sports on the mental health of children and adolescents with disabilities. To assess the risk of bias, the Rob 2.0 tool will be employed for RCTs, and the ROBINS-I tool for CTs. For longitudinal and cross-sectional studies, the National Institute of Health’s Study Quality Assessment Tool for Observational Cohort and Cross-sectional Studies will be used. The review process will be conducted using Covidence, possibly utilizing JASP software for meta-analysis if the retrieved studies exhibit sufficient homogeneity. Data that cannot be included in the meta-analysis will be synthesized using the Synthesis without Meta-Analysis (SWiM) tool. Furthermore, the Consolidated Framework for Implementation Research (CFIR) will provide a framework consisting of five broad domains: intervention characteristics, outer setting, inner setting, characteristics of individuals, and the process of implementation.
Ecological complexity of zoonotic malaria in macaque natural hosts
Understanding health inequalities based on socio-economic factors and geographical location in renal cell carcinoma: A large-scale national cohort study in England.
464 Background: Kidney cancer is 7 th most common cancer in England with renal cell carcinoma (RCC) accounting for about 80% of all cases of kidney cancer. It has well established that the incidence and mortality rates of RCC are strongly associated with four main risk factors, including family history, lifestyle, environment, and occupation. In addition, unequal access to improvements in RCC cancer treatment and limited access to screening and diagnosis, significantly contribute to the difference observed in survival rate. Methods: We aim to assess the association between area-level measures of socioeconomic deprivation, from the 20% most deprived of the population (quintile 1) to the 20% least deprived (quintile 5), or geographical regions in England, with both the diagnosis and treatment of RCC, over five years from April 2019 to March 2024. This study utilized patient-level data for primary and metastatic renal cancer (ICD-10: C64) by organisation, procedure, ethnicity, age group and deprivation quintile from Hospital Episode Statistics (HES). Results: Among 54,535 included patients, 9,935 (18.2%) came from the most deprived quintile and 11,330 (20.8%) from the least deprived quintile with a mean age of 62 years across all patients. Of included patients, 43,290 (79.3%) were Caucasian (white) and the remaining 14,235 patients came from other ethnic groups. In total, 61.0% of patients were middle aged (aged from 45 to 74), with 35.0% elderly (75 and above) and 5.4% classed as young (below 45). Caucasian populations have higher rates of metastatic disease (34.6%) vs non white (29.6%). Prevalence of metastatic disease increases with age (24.1% vs 33.3% vs 34.6% in young, middle aged and elderly respectively). Higher deprivation is associated with lower rates of nephrectomy (42.3% in most deprived vs 43.6% in least deprived). Patients in areas of higher deprivation are on average younger than those in least deprived areas (57 years in most deprived vs 64 in least deprived) while non-white renal cancer patients are also typically younger (57 non-white vs 64 white). The Midlands (central England) region is associated with the highest rates of metastatic cancer (37.4%) while North East & Yorkshire (30.8%) and London (31.1%) has the lowest metastatic disease rates. Conversely, total nephrectomy rates are highest in North East & Yorkshire while they are lowest in the South West region and London (46.6% vs 42.8% vs 43.0% respectively). Conclusions: This study presents the most recent and extensive RCC data from England, exploring the impact of socioeconomic status and geographical location in diagnosis and management of RCC. These findings could facilitate targeted initiatives to improve health inequity across regions in England.
<i>NECTIN4</i> RNA expression and clinical outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC): Exploratory analyses from JAVELIN Bladder 100.
827 Background: Nectin-4 is widely expressed in UC tumors, although protein expression levels vary between patients. Prior analyses have suggested that low overall Nectin-4 expression based on immunohistochemistry may be associated with worse outcomes in patients with advanced UC irrespective of treatment. We report exploratory biomarker analyses from the JAVELIN Bladder 100 phase 3 trial evaluating response to 1L PBC and survival outcomes with avelumab administered as 1L switch-maintenance treatment in subgroups defined by tumor NECTIN4 RNA expression. Methods: In JAVELIN Bladder 100 (NCT02603432), patients with unresectable la/mUC without progression after 4-6 cycles of 1L PBC were randomized to receive avelumab 1L maintenance + best supportive care (BSC) or BSC alone. Whole-transcriptome profiles in tumor samples (primary tumors in ≈75%) were generated using RNA sequencing, and transcript levels were quantified using Personalis ACE technology. NECTIN4 RNA expression was assessed as a continuous variable for subgroups defined by response to 1L PBC, and as a dichotomous variable (median split) for survival analyses. Results: In biomarker-assessable patients enrolled in JAVELIN Bladder 100, no significant differences were observed in tumor NECTIN4 RNA expression in patients who had complete response (n=149), partial response (n=261), or stable disease (n=150) to 1L PBC (Kruskal-Wallis p=0.192). In subgroups with high or low NECTIN4 RNA expression, overall survival (OS) and progression-free survival (PFS) improvements with avelumab + BSC vs BSC alone were consistent with improvements observed in the overall study population (Table). No significant differences in OS and PFS were observed between subgroups with high or low NECTIN4 RNA expression within the avelumab + BSC (p=0.26 and 0.89) and BSC alone (p=0.34 and 0.94) arms. Limitations include ad hoc exploratory analysis and potential selection bias. Conclusions: Exploratory analyses from JAVELIN Bladder 100 suggest that NECTIN4 RNA expression was not prognostic or predictive of level of response to 1L PBC or survival with avelumab 1L maintenance treatment in patients with la/mUC without progression after 1L PBC. Clinical trial information: NCT02603432 . Avelumab + BSC BSC alone High NECTIN4 RNA expression n=139 n=140 Median OS (95% CI), months 22.0 (18.2-30.9) 14.8 (12.9-19.4) Median PFS (95% CI), months 5.65 (4.60-9.00) 3.29 (1.97-3.75) Low NECTIN4 RNA expression n=145 n=136 Median OS (95% CI), months 30.0 (21.4-35.2) 18.7 (13.7-25.5) Median PFS (95% CI), months 5.65 (3.81-9.95) 2.20 (1.91-3.71)
Prostate cancer risk groups by PSMA-PET PROMISE (PPP): Results from an international multi-center registry study.
266 Background: We previously established prognostic nomograms of PSMA-PET standardized by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria in a large single-center cohort. Now, we reassess the PSMA-PET PROMISE (PPP) prognostic nomograms in a large international multi-center registry study with overall survival follow-up. Methods: We included patients with histologically proven prostate cancer who underwent PSMA-PET at 20 hospitals in Germany, Italy, Sweden, Netherlands, Belgium, Slovakia, Austria, United States and Australia between 2014 and 2021. PSMA-PET was standardized by molecular imaging TNM (miTNM). Total tumor volume in L, PSMA expression score and overall survival follow-up were obtained. The cohort was randomly split 2:1 into development and validation cohorts. In the development cohort we assessed PPP predictors and created visual and quantitative PPP nomograms based on Cox regression models with least absolute shrinkage and selection operator penalty for overall survival. Performance of both nomograms was measured in the validation cohort using Harrell´s C-index and calibration plots. Head-to-head comparison to the NCCN risk score was examined by ROC-curves. Results: We analyzed 6128 male patients (4075 development and 2053 validation) across all disease stages with 1915 (31.2%) reported deaths and median follow-up of 4.77 years [IQR 3.38-6.44]. Predictors in the visual PPP nomogram were distant metastases (extrapelvic nodal metastases [M1a], bone metastases [M1b; oligometastatic disease, disseminated or diffuse marrow involvement], and organ metastases [M1c]), PSMA expression score and total tumor lesion count. Predictors in the reassessed quantitative PPP nomogram were distant metastases (M1a, M1b, and M1c), tumor volume and PSMA expression score. C-indices (95% CI) in the validation cohort were 0.812 (0.794; 0.830) for the visual and 0.821 (0.805; 0.837) for the quantitative nomogram, respectively. For three-tier stratification (high, intermediate, low risk), accuracy of both PPP nomograms was superior when compared to the NCCN risk score (n=3638, visual: AUC 0.828 vs. 0.756; p<0.0001 and quantitative: AUC 0.837 vs. 0.756; p<0.0001). Conclusions: PSMA-PET PROMISE nomograms in an international multi-center study accurately stratify high vs. intermediate vs. low-risk groups for overall survival across all stages of prostate cancer and yield superior accuracy compared to the NCCN risk score. Follow-up continues in the PROMISE Registry (NCT06320223, promise-pet.org).
Impact of specimen type on digital histopathology-based multimodal artificial intelligence (MMAI) biomarker risk score: Whole slide image vs tissue microarray.
400 Background: The ArteraAI Prostate Test (v1.2), a digital pathology-based multimodal artificial intelligence (MMAI) biomarker, was developed and validated using clinical data (age, T stage, PSA) and whole slide images (WSI) from prostate biopsies to prognosticate risk of 10-year distant metastasis for men with localized prostate cancer (PCa). This study aimed to apply the MMAI biomarker to prostatectomy (RP) tissue microarray (TMA) samples and, for the first time, explore the impact of using RP TMA in place of RP WSI on MMAI scores. Methods: The analysis cohort included men with localized PCa who had undergone RP. Black men were matched in a 4:1 ratio to White men with similar baseline characteristics. MMAI scores were generated using digitized TMA and WSI from each patient’s RP specimen. The normality of score distribution was examined using the Shapiro-Wilk (SW) test. Wilcoxon signed rank (WSR) test and Spearman rank coefficients were used to compare TMA-derived and WSI-derived scores. Analyses were performed in the entire cohort and Black or White subgroups. Results: Paired MMAI scores were generated for 98 men with a median age of 58, PSA 5.4 ng/mL, the majority were Gleason grade groups 1-2 (84%), 82% were Black. The distribution of TMA-derived scores (SW test, P=0.04) was more skewed than that of WSI-derived scores (SW test, P=0.39). The median MMAI score was significantly higher for WSI images than for TMA images in all men and in Black men (WSR test, P<0.01). There was no notable variation in either set of scores by race (Table). The correlation coefficient was 0.496 (0.519 for Black men). Using pre-specified cutoffs in MMAI scores (high, intermediate, low), 30/98 (31%) men were classified into lower risk groups by TMA than WSI scores (23/80 [29%] Black men). Conclusions: In this application of the MMAI biomarker to RP samples within this cohort of primarily Black men, we found WSI-derived and TMA-derived MMAI scores to be significantly different but moderately correlated. Given that TMA represents only a portion of WSI and sampling location may impact the results, TMA may be insufficiently reliable for MMAI score generation. MMAI biomarkers that are robust across different specimen preparation methods have potential for clinical and research utility; these hypothesis-generating results support further research along these lines. Continuous MMAI scores and categorical MMAI risk group distribution using WSI- and TMA-derived images by subgroup. WSI-derived score TMA-derived score Patients Continuous 1 Low 2 Int 2 High 2 Continuous 1 Low 2 Int 2 High 2 All 0.47(0.44-0.53) 0(0%) 69(70%) 29(30%) 0.37(0.33-0.42) 6(6%) 87(89%) 5(5%) Black 0.47(0.45-0.51) 0(0%) 58(73%) 22(27%) 0.37(0.33-0.43) 4(5%) 73(91%) 3(4%) White 0.48(0.43-0.54) 0(0%) 11(61%) 7(39%) 0.37(0.32-0.41) 2(11%) 14(78%) 2(11%) 1 Presented as median (IQR). 2 Presented as n (%).
Oxygen impurities in AlN and their impact on optical absorption
Oxygen is a common impurity in AlN samples. Using hybrid density functional calculations, we investigate the role of substitutional oxygen (ON) in the optical absorption. We construct configuration coordination diagrams for ON and related complexes. Our results indicate that an optical transition involving ON− (a DX center) gives rise to an absorption band peaked at 2.22 eV, suggesting it is a source of the absorption band with an onset at ∼ 2 eV observed in oxygen-containing samples. We also propose that neutral ON–DX complexes can form, which would give rise to absorption peaking at 3.06 eV. In addition, we find that oxygen, in spite of its DX character, may behave as an “optically shallow donor” and be involved in optical transitions from deep defect states to the conduction band. This observation provides an alternative physical mechanism for the optical absorption bands observed in AlN samples in the visible and ultraviolet (UV) region.
The accuracy of capture per unit effort in predicting density of a cryptic snake was more sensitive to reductions in spatial than temporal coverage
A critical component of monitoring wildlife populations is understanding changes in population size or abundance. However, for most populations a complete census is not possible; thus, trends or abundance need to be estimated through alternative means, such as indexes. An important aspect of using indexes, such as capture per unit effort (CPUE), is validating them as accurate or precise predictors of population trends or abundance. We completed such analyses using data collected from visual surveys and trapping for brown treesnakes (Boiga irregularis) within a 5-ha enclosure that was undergoing a continuous population decline. During a ~ 6-year period, we censused and marked the snake population to fully enumerated the population, with new individuals resulting from births and removals resulting only from mortality (natural or experimental). From trapping and visual surveys, we were also able to calculate CPUE as a function of trap nights or km surveyed and used regressions to forecast snake density (snakes/km) in the enclosure from CPUE. We also rarefied the true dataset to measure whether reductions in sampling intensity, either temporally or spatially, affected the accuracy or precision in predicting snake density from CPUE. We found that trap CPUE demonstrated no statistical relationship to density based on our study methods. CPUE during visual surveys did predict actual density, with sufficient spatial and temporal sampling intensity. CPUE from visual surveys was relatively robust against reductions in temporal sampling when spatial intensity remained high. However, reductions in the spatial area covered to less than 50% of the enclosure rapidly reduced the accuracy and precision in using CPUE to forecast density. Our results indicate that visual surveys are a relatively accurate measure of true density for brown treesnakes, given sufficient spatial sampling effort. The spatial area of coverage required for CPUE to accurately predict changes in abundance was, however, intense with > 50% of the spatial area required to be sampled on a given sampling night. Our results indicate that CPUE is only reliable as an index of abundance or population trends for cryptic snakes, if sampling effort covers most of the landscape over which populations are being estimated.